The drama surrounding Sarepta's gene therapy, where a top regulator was ousted after political pushback and later reinstated, shows the FDA is now more amenable to outside influence. This case study indicates that presidential and activist pressure can directly impact regulatory enforcement and personnel decisions, moving beyond purely scientific considerations.

The FDA issued Complete Response Letters for both REGENXBIO's gene therapy and DISC Medicine's oral drug, signaling high scrutiny for accelerated approvals. The agency specifically cited concerns over the relevance of surrogate endpoints and required more robust clinical trial data, highlighting the risks of relying on non-traditional approval pathways.

Despite positive clinical data for its Duchenne gene therapy, REGENXBIO is delaying its FDA submission until 2027 due to leadership turmoil at the agency. This demonstrates how political and administrative uncertainty within a regulatory body can directly stall corporate timelines and delay patient access to potentially life-saving treatments.

After a decade on the market and multiple shifts in endpoints, Sarepta's definitive Phase 3 study for its DMD drugs failed. This outcome casts doubt on the entire accelerated approval framework for slowly progressive diseases, where surrogate endpoints may not translate to clinical benefit, leaving regulators and patients in a difficult position.

A key driver of current FDA turmoil is the stark, real-time contradiction between the agency's published guidelines and its recent decisions. This rapid shifting of regulatory goalposts creates an unprecedented level of uncertainty and frustration for drug developers and investors.

The FDA halted two REGENXBIO gene therapies with similar constructs after a safety event in one trial. However, it spared a third therapy from the same company that used a different design, indicating regulators assess risk at the technology platform level, not just the company or disease level.

The FDA's current leadership appears to be raising the bar for approvals based on single-arm studies. Especially in slowly progressing diseases with variable endpoints, the agency now requires an effect so dramatic it's akin to a parachute's benefit—unmistakable and not subject to interpretation against historical data.

Previously considered a capital-efficient area due to regulatory flexibility, the rare disease and gene therapy space is now perceived as high-risk. The FDA is applying greater scrutiny and tightening standards, making development more unpredictable for sponsors.

The FDA's inconsistency and the growing gap between its guidance and actions have made regulatory risk a primary evaluation factor for investors, complicating trial design, causing delays, and raising the cost of capital for biotechs.